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Abstract
Background:  Group A beta hemolytic streptococcus (GABHS) pharyngitis is a common
childhood illness. Penicillin remains the gold standard therapy, but macrolides are indicated for the
penicillin allergic patient, and are often used for convenience.
Methods:  We conducted a surveillance study of children with pharyngitis and positive
streptococcal rapid antigen testing from 10/05 to 10/06 at 2 sites (A & B). Demographics,
treatment, and resistance data was collected and compared to previous data from 2002.
Erythromycin (EM) resistance was determined by disk diffusion and E-test on 500 isolates. Pulse
field gel electrophoresis (PFGE) was performed to measure genetic relatedness of isolates.
StatXact version 8 software (Cytel Inc., Cambridge, MA) was utilized to perform Fisher's exact test
and exact confidence interval (CI) analysis.
Results:  There were no differences in resistance rates or demographic features, with the
exception of race, between sites A & B. EM resistance was 0 in 2002, 3.5% in 2005-06 at site A, and
4.5% in 2005-06 at site B. 3/7 and 3/9 had inducible resistance at A and B respectively. 8 isolates
had relatedness ≥80%, 5 of which were 88% homologous on PFGE.
Conclusion: Community macrolide resistance has increased following increased macrolide use.
These results may have treatment implications if use continues to be high.
Background
Group A streptococcal pharyngitis (GABHS) is a common
childhood infection that is most frequent in the school
age child [1]. Antimicrobial therapy is pursued largely for
the prevention of rheumatic fever, and organism eradica-
tion virtually eliminates this risk [2]. Penicillin is the gold
standard therapy for GABHS infection, and penicillin
resistance has never been documented [3]. Macrolides are
recommended for the penicillin allergic patient. However,
they are being increasingly used for convenience, due to
once daily dosing, shorter course of therapy, and perhaps
better taste. As macrolide use has increased, resistance has
been noted with resultant bacteriologic failures [3-5].
There are two different macrolide resistance mechanisms
that Group A streptococcus may carry. The first is an active
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efflux mechanism caused by the macrolide efflux gene, or
mef A gene, which confers resistance to 14 and 15 mem-
bered macrolides, but not to 16 membered macrolides,
lincosamides, or streptogramin b [3,5]. This is referred to
as the M phenotype. The second is caused by erythromy-
cin resistance methylase, or erm gene. The erm gene
causes target site modification within the 50s ribosomal
subunit. It is expressed in either an inducible or constitu-
tive manner, which results in resistance to macrolides, lin-
cosamides, and streptogramin b antibiotics [6].
Reports of macrolide resistance prevalence are varied from
country to country throughout the world. Portugal has
reported resistance rates of 27%, Belgium 13%, Spain
30%, and Italy 40% [4,6-8]. While widespread macrolide
resistance has been reported in several European coun-
tries, low level resistance has been predominantly
reported in the US [9]. However, more recent studies have
shown an increase in resistance rates to 6-7%, with pock-
ets of higher resistance at differing times between 10-20%
[10-12]. This increase in resistance has followed an
increase in macrolide use on a national level [13]. Both
inpatient and outpatient macrolide prescriptions
increased in our institution by 11% and 15% respectively
from 2002-04. Our study is an evaluation of local mac-
rolide resistance in 2 separate clinical settings; an urban
teaching hospital, and a community pediatric office, with
comparison of local previous macrolide resistance data.
Methods
This was a prospective surveillance study of 400 children
with positive rapid streptococcal antigen testing, and
symptomatology consistent with streptococcal pharyngi-
tis. A power calculation was performed and revealed that
with a sample size of 400 we would have 90% power to
detect a 10% shift in macrolide resistance prevalence from
near zero to 10%. Institutional review board approval was
obtained.
Our urban teaching institution was designated as site A,
and the community pediatric office was designated as site
B. Convenience sampling of 8 specimens per week was
obtained from each site from October 2005 to October
2006. Specimens were inoculated on Trypticase-Soy agar
with 5% sheep blood. (Remel Inc., Lenexa, KS) Isolates
were confirmed to be GABHS by latex antigen agglutina-
tion. Susceptibility testing was performed by double disc
(D- test) diffusion method, which allowed for identifica-
tion of phenotype in resistant isolates [14]. D-testing was
performed with a 2 μg clindamycin disc and a15 μg eryth-
romycin disc placed 12 mm apart, with subsequent evalu-
ation for zone blunting around the clindamycin disc.
Resistant isolates were then further tested to confirm min-
imum inhibitory concentration (MIC). Standard Clinical
and Laboratory Standards Institute (CLSI) plating and
susceptibility techniques were utilized, as well as break-
points to determine resistance [15,16]. Baseline demo-
graphic characteristics including age, race, payor status,
treatment, and zip codes were collected. Race was classi-
fied by parent report, and was included to characterize the
patient population at each site.
Pulse field gel electrophoresis (PFGE) was performed on
in situ Sfi1 digests of chromosomal DNA from all available
resistant isolates using a CHEF DR III System (Bio-Rad,
Hercules, CA) at 6 V/cm, 14°C, 120° included angle, with
switching from 5 to 15 s for 10 hours, followed by switch-
ing from 15 to 60 s for 13 hours [17,18]. Sfi1 is a restric-
tion enzyme that produces 5-7 well separated DNA
fragments. [19]. Images of ethidium-bromide stained gels
were archived using a Bio-Rad Gel Doc 1000 System.
PFGE profiles were analyzed using BioNumerics v 4.01
(Applied Maths, St-Martens-Latern, Belgium). Isolates
were given specific strain designations based on at least
80% similarity. In addition PFGE was performed on 2 sus-
ceptible isolates obtained within 2 weeks of each resistant
isolate, in order to make direct genetic comparison of each
resistant isolate to current circulating susceptible isolates.
Comparison was made between site A and site B, as well
as previous site A data from 2002 using Fisher's exact test
and exact confidence interval (CI) analysis. We used a
two-sided alpha level of 0.05 and 95% confidence limits
throughout. These analyses used StatXact version 8 soft-
ware (Cytel Inc., Cambridge, MA).
Results
Sites A and B showed no significant differences in demo-
graphic patient characteristics on age, sex, payor status,
and treatment (Table 1). There was a difference in racial
composition with 30% white, 20% Hispanic, 47% Afri-
can-American, 1% Asian, and 2% Other at Site A, and
80% white, 4% Hispanic, 7% African-American, 0%
Asian, and 8% Other at Site B (p = 0.0001).
There were a total of 16 resistant isolates, 7 from site A in
2005-2006 (3.5%), and 9 from site B in 2005-2006
(4.5%) (Table 2). There was no difference in resistance
between the two sites (p = 0.80, 95% CI -0.20, 0.31). No
isolates with complete resistance were found at site A in
Table 1: Demographic and Treatment Data
Site A Site B
Median/Mean age 6 yrs/7.5 yrs 6 yrs/7.5 yrs
Male 104/200 (52%) 105/200 (53%)
Caucasian 61/200 (30%) 161/200 (80%)
Medicaid 131/200 (65%) 108/200 (52%)
Penicillin/amoxicillin 178/200 (91%) 179/200 (90%)
Oral cephalosporin 8/200 (4%) 20/200 (10%)
Other/none 14/200 (7%) 1/200 (0.5%)Annals of Clinical Microbiology and Antimicrobials 2009, 8:33 http://www.ann-clinmicrob.com/content/8/1/33
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2002, and the increase in resistance from 2002 to 2005-
2006 at site A alone was not statistically significant (p =
0.1, 95% CI -0.11, 0.41). However, the combination of
sites A and B revealed a statistically significant increase in
resistance (p = 0.05, 95% CI 0.004, 0.25). There were an
additional 4 isolates with intermediate resistance noted in
2005-2006, 1 and 3 at site A and B respectively. There were
two isolates with intermediate resistance noted in 2002.
D-zone testing revealed inducible clindamycin resistance,
indicating erm phenotype, in 43% (3/7) of the isolates at
site A, and 33% (3/9) at site B. (Table 2) Macrolide only
resistance was found in the 10 remaining isolates, which
denotes Mef A phenotype. MIC's for erm resistant strains
were uniformly >256 μg/ml and 12-32 μg/ml for the Mef
A phenotype. Constitutive resistance was not found.
Seasonal differences in the resistance rate were evaluated
by noting the number of resistant isolates found per
month, and by dividing the year into 4 seasons. The sea-
sons were divided into December, January and February
for winter months, March, April, and May for spring
months, June, July, and August for summer months, and
September, October, and November for fall months.
There were a small number of resistant isolates seen in the
summer and fall seasons, with only 2 and 3 being noted
respectively. However, an increase in the number of resist-
ant isolates was seen in the winter and spring months at 4
and 7 respectively.
PFGE was initially performed with traditional SmaI
restriction enzyme, commonly employed for analysis of
Gram positive isolates. However, the macrolide resistant
strains of the mef A phenotype were not cleaved, necessi-
tating the use of Sfi1 enzyme on all isolates for PFGE anal-
ysis. [20] Twelve resistant isolates were available for PFGE
performance. An additional 21 susceptible isolates under-
went PFGE testing for comparison of potential clones.
(Figure 1) Isolates were classified by site, week number of
the study, and numbered 1-8 from the respective week.
Eight of the 12 resistant isolates were found to have ≥80%
homology, 6 of which were obtained from site B. (Figure
2) However, one of the patients who had a related strain
isolated at site A lives within the site B zip code area. Five
of the 8 isolates were in clusters with ≥88% homology,
and 7 isolates were D zone test negative demonstrating M
phenotype resistance. (Figure 2) We compared PFGE pat-
terns of relatedness among resistance genes in relation to
their geographic proximity within the zip code areas sur-
rounding site A and site B. There were no genetically
related isolates from site A (0/5), however 6 of the 7
(85%) resistant isolates from site B that underwent PFGE
had homology of ≥ 80%.
Discussion
Macrolide resistance was found in our community, which
represents a difference in findings from a previous analy-
sis in 2002. Our rate of macrolide resistance was noted to
be similar to rates reported nationally. Local resistance,
MIC ≥1 μg/ml, has increased from zero in 2002 to 4.5%
in 2005-06, and has become apparent after a documented
increase in macrolide use. This increase is not as signifi-
cant as has been noted in other countries with high rates
of macrolide use [4,6-8,21,22]. However, those countries
had higher rates of macrolides use than is typically seen in
the US, and therefore should be expected to have an ele-
vated resistance rate that correlates with their use. Never-
theless, this data confirms that as rates of antibiotic use
increase, resistance rates increase concomitantly. This data
then underscores the importance of judicious antimicro-
bial use.
Nearly 40% of resistant isolates were D-zone test positive,
which signifies clindamycin resistance in 1.5% of our
GABHS isolates. Routine D-zone testing has not histori-
cally been part of GABHS testing, as GABHS is uniformly
susceptible to penicillin, and typically requires no further
workup past the speciation stage. However, a number of
invasive GABHS infections occur yearly with a small per-
centage of deaths, which makes knowledge of susceptibil-
ities of greater importance. Clindamycin has been utilized
in the treatment of invasive infections thought to be
caused by a toxin producing strain of GABHS for down
regulation of toxin production [23-25]. This makes com-
plete susceptibility testing an important feature when
choosing therapy for infection. Although Kirby Bauer test-
ing would provide knowledge of constitutive clindamycin
resistance; it would provide no information regarding
inducible clindamycin resistance. This information is
important, as it may serve to alter the clinical care of the
patient in the setting of invasive infection where the
length of therapy is typically prolonged, raising the likeli-
hood of inducible resistance resulting in treatment fail-
ures during the course of treatment.
Previous literature has reported difficulty in enzymatic
degradation of Mef A resistant GAS isolates with SmaI
enzyme [14]. We encountered the same difficulty, neces-
sitating repeating PFGE testing with SfiI enzyme for all
isolates. The inability of SmaI to degrade resistant isolates
Table 2: Current GABHS Resistance Rates
Site A Site B
Macrolide-Susceptible 192/200 (96%) 188/200 (94%)
Macrolide-Intermediate 1/200 (0.5%) 3/200 (1.5%)
Macrolide-Resistant 7/200 (3.5%) 9/200 (4.5%)
Inducible Clindamycin Resistancea 3/7 (42.9%) 3/9 (33.3%)
a Determined by double disk diffusion (D-test)Annals of Clinical Microbiology and Antimicrobials 2009, 8:33 http://www.ann-clinmicrob.com/content/8/1/33
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PFGE of macrolide-resistant and susceptible Streptococcus pyogenes isolates Figure 1
PFGE of macrolide-resistant and susceptible Streptococcus pyogenes isolates. PFGE was performed on 2 susceptible 
isolates obtained within 2 weeks of each resistant isolate at the corresponding site for genetic comparison. Each isolate is iden-
tified by site of origin (A or B), week in which it was obtained (1-26), and the isolate number within the week (1-8). The den-
dogram, to the left, denotes the percent of genetic relatedness between resistant and susceptible isolates. The level at which 
the vertical line transect the horizontal line from the PFGE of each isolate determines its homology based on the percent scale 
above the dendogram. Twelve resistant and 21 susceptible isolates are pictured. Resistant isolates are identified as (R).Annals of Clinical Microbiology and Antimicrobials 2009, 8:33 http://www.ann-clinmicrob.com/content/8/1/33
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has been theorized to be due to a modification within the
genetic element that encodes the M-resistance phenotype
[20]. Out of 5 resistant isolates, 4 (≥80%) were found to
be D-zone test negative which indicates M phenotype of
resistance. Resistance at site A was genetically diverse, but
site B isolates were found to have more homology overall,
with 6/7 (85.6%) isolates revealing ≥80% similarity, indi-
cating the likelihood of a single clone [19].
Although this was a large sample size, we detected a small
number of resistant isolates, which limits the level of sta-
tistical precision. Still, our data reveal a trend in our local
community that mirrors national resistance rates. Two
distinct areas of the community were evaluated which
allows for broader generalizations regarding resistance
rates overall than would be reasonable if only one site par-
ticipated in the study.
It was an interesting finding that site B had increased
homology of the resistant isolates when compared to site
A. This may be related to site B being a relatively smaller
community than site A with the potential for easier spread
of a single resistant clone. This theory would be better
tested with comparison of several smaller community
sites along with obtaining an adequate sample size to
appropriately power the study.
Conclusion
Macrolide resistance has emerged in our local commu-
nity, as well as on a national level. Although the overall
percentages are not high at this point, it is becoming an
increasingly important problem with continued high lev-
els of macrolide use for upper respiratory tract infections.
These results underscore the importance of identification
of a bacterial infection prior to antibiotic use, with subse-
quent susceptibility testing on all invasive isolates.
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